Comorbidities in the management of patients with lung cancer

European Respiratory Journal

Volumn 49, Issue 3, 2017, Pages

  Leduc, Charlotte ^a   Antoni, Delphine ^b   Charloux, Anne ^c   Falcoz, Pierre Emmanuel ^a   Quoix, Elisabeth ^a  

^a HÔPITAL CIVIL   (France)

^b CENTRE PAUL STRAUSS   (France)

^c Physiology and Functional Explorations Dept   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ARTICLE; BRONCHIECTASIS; CANCER IMMUNOTHERAPY; CANCER PATIENT; CANCER RADIOTHERAPY; CANCER SURGERY; CARDIOVASCULAR DISEASE; CHRONIC OBSTRUCTIVE LUNG DISEASE; COMORBIDITY; DIABETES MELLITUS; DISEASE SEVERITY; EMPHYSEMA; FIBROSING ALVEOLITIS; HEALTH INSURANCE; HEPATITIS B; HEPATITIS C; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INTERSTITIAL LUNG DISEASE; KIDNEY FAILURE; LUNG CANCER; PNEUMONIA; POPULATION RESEARCH; PRIORITY JOURNAL; RADIATION HAZARD; RESPIRATORY TRACT DISEASE ASSESSMENT; RISK FACTOR; SMOKING; SOCIAL PSYCHOLOGY; SYSTEMIC THERAPY; TRANSTHORACIC BIOPSY; TUBERCULOSIS; AGED; COMPLICATION; DISEASE MANAGEMENT; DRUG THERAPY; EPIDEMIOLOGY; IMMUNOTHERAPY; LUNG EMPHYSEMA; LUNG FIBROSIS; LUNG TUMOR; MOLECULARLY TARGETED THERAPY; RADIOTHERAPY; RESPIRATORY FAILURE; SURGERY; X-RAY COMPUTED TOMOGRAPHY;

AGED; COMORBIDITY; DISEASE MANAGEMENT; DRUG THERAPY; HUMANS; IMMUNOTHERAPY; LUNG DISEASES, INTERSTITIAL; LUNG NEOPLASMS; MOLECULAR TARGETED THERAPY; PULMONARY EMPHYSEMA; PULMONARY FIBROSIS; RADIOTHERAPY; RESPIRATORY INSUFFICIENCY; SMOKING; SURGICAL PROCEDURES, OPERATIVE; TOMOGRAPHY, X-RAY COMPUTED;

EID: 85022140508     PISSN: 09031936     EISSN: 13993003     Source Type: Journal    
DOI: 10.1183/13993003.01721-2016     Document Type: Article

References (131)

1. de Torres JP, Marín JM, Casanova C, et al. Lung cancer in patients with chronic obstructive pulmonary disease--incidence and predicting factors. Am J Respir Crit Care Med 2011; 184: 913–919.
2. Young RP, Hopkins RJ, Christmas T, et al. COPD prevalence is increased in lung cancer, independent of age, sex and smoking history. Eur Respir J 2009; 34: 380–386.
3. Wasswa-Kintu S, Gan WQ, Man SFP, et al. Relationship between reduced forced expiratory volume in one second and the risk of lung cancer: a systematic review and meta-analysis. Thorax 2005; 60: 570–575.
4. Henschke CI, Yip R, Boffetta P, et al. CT screening for lung cancer: importance of emphysema for never smokers and smokers. Lung Cancer 2015; 88: 42–47.
5. Zhai R, Yu X, Shafer A, et al. The impact of coexisting COPD on survival of patients with early-stage non-small cell lung cancer undergoing surgical resection. Chest J 2014; 145: 346–353.
6. Sunnetcioglu A, Alp HH, Sertogullarından B, et al. Evaluation of oxidative damage and antioxidant mechanisms in COPD, lung cancer, and obstructive sleep apnea syndrome. Respir Care 2016; 61: 205–211.
7. Vakkila J, Lotze MT. Inflammation and necrosis promote tumour growth. Nat Rev Immunol 2004; 4: 641–648.
8. Dixon K, Kopras E. Genetic alterations and DNA repair in human carcinogenesis. Semin Cancer Biol 2004; 14: 441–448.
9. Pillai SG, Ge D, Zhu G, et al. A genome-wide association study in chronic obstructive pulmonary disease (COPD): identification of two major susceptibility loci. PLoS Genet 2009; 5: e1000421.
10. Wauters E, Smeets D, Coolen J, et al. The TERT-CLPTM1L locus for lung cancer predisposes to bronchial obstruction and emphysema. Eur Respir J 2011; 38: 924–931.
11. Maltby S, Plank M, Tay HL, et al. Targeting MicroRNA function in respiratory diseases: mini-review. Respir Physiol 2016; 21.
12. Neves PC, Guerra M, Ponce P, et al. Non-cystic fibrosis bronchiectasis. Interact Cardiovasc Thorac Surg 2011; 13: 619–625.
13. Kuper H, Adami HO, Trichopoulos D. Infections as a major preventable cause of human cancer. J Intern Med 2000; 248: 171–183.
14. Bobba RK, Holly JS, Loy T, et al. Scar carcinoma of the lung: a historical perspective. Clin Lung Cancer 2011; 12: 148–154.
15. Chung W-S, Lin C-L, Lin C-L, et al. Bronchiectasis and the risk of cancer: a nationwide retrospective cohort study. Int J Clin Pract 2015; 69: 682–688.
16. Raviglione M, Sulis G. Tuberculosis 2015: burden, challenges and strategy for control and elimination. Infect Dis Rep 2016; 8: 6570.
17. Falzon D, Kudjawu YC, Desenclos JC, et al. Stopping TB in Europe: some progress but still not there. Euro Surveill 2008; 13: ppii: 8073.
18. Coussens LM, Werb Z. Inflammation and cancer. Nature 2002; 420: 860–867.
19. Ballaz S, Mulshine JL. The potential contributions of chronic inflammation to lung carcinogenesis. Clin Lung Cancer 2003; 5: 46–62.
20. Shiels MS, Albanes D, Virtamo J, et al. Increased risk of lung cancer in men with tuberculosis in the alpha-tocopherol, beta-carotene cancer prevention study. Cancer Epidemiol Biomarkers Prev 2011; 20: 672–678.
21. Chen Y-M, Chao J-Y, Tsai C-M, et al. Shortened survival of lung cancer patients initially presenting with pulmonary tuberculosis. Jpn J Clin Oncol 1996; 26: 322–327.
22. Yu Y-H, Liao C-C, Hsu W-H, et al. Increased lung cancer risk among patients with pulmonary tuberculosis: a population cohort study. J Thorac Oncol 2011; 6: 32–37.
23. Liang H-Y, Li X-L, Yu X-S, et al. Facts and fiction of the relationship between preexisting tuberculosis and lung cancer risk: a systematic review. Int J Cancer 2009; 125: 2936–2944.
24. Wu C-Y, Hu H-Y, Pu C-Y, et al. Pulmonary tuberculosis increases the risk of lung cancer: a population-based cohort study. Cancer 2011; 117: 618–624.
25. Heuvers ME, Aerts JGJV, Hegmans JP, et al. History of tuberculosis as an independent prognostic factor for lung cancer survival. Lung Cancer 2012; 76: 452–456.
26. Radisky DC, Kenny PA, Bissell MJ. Fibrosis and cancer: do myofibroblasts come also from epithelial cells via EMT? J Cell Biochem 2007; 101: 830–839.
27. Wellner U, Schubert J, Burk UC, et al. The EMT-activator ZEB1 promotes tumorigenicity by repressing stemness-inhibiting microRNAs. Nat Cell Biol 2009; 11: 1487–1495.
28. Hubbard R, Venn A, Lewis S, et al. Lung cancer and cryptogenic fibrosing alveolitis: a population-based cohort study. Am J Respir Crit Care Med 2000; 161: 5–8.
29. Harris JM, Johnston IDA, Rudd R, et al. Cryptogenic fibrosing alveolitis and lung cancer: the BTS study. Thorax 2010; 65: 70–76.
30. Le Jeune I, Gribbin J, West J, et al. The incidence of cancer in patients with idiopathic pulmonary fibrosis and sarcoidosis in the UK. Respir Med 2007; 101: 2534–2540.
31. Goto T, Maeshima A, Oyamada Y, et al. Idiopathic pulmonary fibrosis as a prognostic factor in non-small cell lung cancer. Int J Clin Oncol 2014; 19: 266–273.
32. Park J, Kim DS, Shim TS, et al. Lung cancer in patients with idiopathic pulmonary fibrosis. Eur Respir J 2001; 17: 1216–1219.
33. Khan KA, Kennedy MP, Moore E, et al. Radiological characteristics, histological features and clinical outcomes of lung cancer patients with coexistent idiopathic pulmonary fibrosis. Lung 2015; 193: 71–77.
34. Daniels CE, Jett JR. Does interstitial lung disease predispose to lung cancer? Curr Opin Pulm Med 2005; 11: 431–437.
35. Janssen-Heijnen ML, Schipper RM, Razenberg PP, et al. Prevalence of co-morbidity in lung cancer patients and its relationship with treatment: a population-based study. Lung Cancer 1998; 21: 105–113.
36. Ambrogi V, Pompeo E, Elia S, et al. The impact of cardiovascular comorbidity on the outcome of surgery for stage I and II non-small-cell lung cancer1. Eur J Cardiothorac Surg 2003; 23: 811–817.
37. IL6R Genetics Consortium Emerging Risk Factors Collaboration, et al.. Interleukin-6 receptor pathways in coronary heart disease: a collaborative meta-analysis of 82 studies. Lancet 2012; 379: 1205–1213.
38. Libby P. Inflammation and cardiovascular disease mechanisms. Am J Clin Nutr 2006; 83: 456S–460S.
39. Hatlen P, Langhammer A, Carlsen SM, et al. Self-reported cardiovascular disease and the risk of lung cancer, the HUNT study. J Thorac Oncol 2014; 9: 940–946.
40. Kravchenko J, Berry M, Arbeev K, et al. Cardiovascular comorbidities and survival of lung cancer patients: Medicare data based analysis. Lung Cancer 2015; 88: 85–93.
41. Janssen-Heijnen MLG, van Erning FN, De Ruysscher DK, et al. Variation in causes of death in patients with non-small cell lung cancer according to stage and time since diagnosis. Ann Oncol 2015; 26: 902–907.
42. Guiguet M, Boué F, Cadranel J, et al. Effect of immunodeficiency, HIV viral load, and antiretroviral therapy on the risk of individual malignancies (FHDH-ANRS CO4): a prospective cohort study. Lancet Oncol 2009; 10: 1152–1159.
43. Hleyhel M, Belot A, Bouvier A-M, et al. Trends in survival after cancer diagnosis among HIV-infected individuals between 1992 and 2009. Results from the FHDH-ANRS CO4 cohort. Int J Cancer 2015; 137: 2443–2453.
44. Lanoy E, Spano J-P, Bonnet F, et al. The spectrum of malignancies in HIV-infected patients in 2006 in France: the ONCOVIH study. Int J Cancer 2011; 129: 467–475.
45. Suneja G, Shiels MS, Melville SK, et al. Disparities in the treatment and outcomes of lung cancer among HIV-infected individuals. AIDS 2013; 27: 459–468.
46. Tron L, Lert F, Spire B, et al. Tobacco smoking in HIV-infected versus general population in France: heterogeneity across the various groups of people living with HIV. PloS One 2014; 9: e107451.
47. Lavolé A, Chouaïd C, Baudrin L, et al. Effect of highly active antiretroviral therapy on survival of HIV infected patients with non-small-cell lung cancer. Lung Cancer Amst Neth 2009; 65: 345–350.
48. Makinson A, Tenon J-C, Eymard-Duvernay S, et al. Human immunodeficiency virus infection and non-small cell lung cancer: survival and toxicity of antineoplastic chemotherapy in a cohort study. J Thorac Oncol 2011; 6: 1022–1029.
49. Moltó J, Moran T, Sirera G, et al. Lung cancer in HIV-infected patients in the combination antiretroviral treatment era. Transl Lung Cancer Res 2015; 4: 678–688.
50. Peng J-W, Liu D-Y, Lin G-N, et al. Hepatitis B virus infection is associated with poor prognosis in patients with advanced non small cell lung cancer. Asian Pac J Cancer Prev 2015; 16: 5285–5288.
51. Lok AS, Liang RH, Chiu EK, et al. Reactivation of hepatitis B virus replication in patients receiving cytotoxic therapy. Report of a prospective study. Gastroenterology 1991; 100: 182–188.
52. Xunrong L, Yan AW, Liang R, et al. Hepatitis B virus (HBV) reactivation after cytotoxic or immunosuppressive therapy--pathogenesis and management. Rev Med Virol 2001; 11: 287–299.
53. Lin G-N, Peng J-W, Xiao J, et al. Hepatitis B virus reactivation in hepatitis B surface antigen seropositive patients with metastatic non-small cell lung cancer receiving cytotoxic chemotherapy: the efficacy of preemptive lamivudine and identification of risk factors. Med Oncol 2014; 31: 119.
54. Bui N, Wong-Sefidan I. Reactivation of hepatitis B virus after withdrawal of erlotinib. Curr Oncol Tor Ont 2015; 22: 430–432.
55. Yeo W, Johnson PJ. Diagnosis, prevention and management of hepatitis B virus reactivation during anticancer therapy. Hepatology 2006; 43: 209–220.
56. Loomba R, Rowley A, Wesley R, et al. Systematic review: the effect of preventive lamivudine on hepatitis B reactivation during chemotherapy. Ann Intern Med 2008; 148: 519–528.
57. Gower E, Estes C, Blach S, et al. Global epidemiology and genotype distribution of the hepatitis C virus infection. J Hepatol 2014; 61: S45–S57.
58. Malaguarnera M, Gargante MP, Risino C, et al. Hepatitis C virus in elderly cancer patients. Eur J Intern Med 2006; 17: 325–329.
59. Fiorino S, Bacchi-Reggiani L, de Biase D, et al. Possible association between hepatitis C virus and malignancies different from hepatocellular carcinoma: a systematic review. World J Gastroenterol 2015; 21: 12896–12953.
60. Vento S, Cainelli F, Longhi MS. Reactivation of replication of hepatitis B and C viruses after immunosuppressive therapy: an unresolved issue. Lancet Oncol 2002; 3: 333–340.
61. de Pree C, Giostra E, Galetto A, et al. Hepatitis C virus acute exacerbation during chemotherapy and radiotherapy for oesophageal carcinoma. Ann Oncol 1994; 5: 861–862.
62. Melisko ME, Fox R, Venook A. Reactivation of hepatitis C virus after chemotherapy for colon cancer. Clin Oncol R Coll Radiol G B 2004; 16: 204–205.
63. Kellum JA, Lameire N, Aspelin P, et al. Work group membership. Kidney Int 2012; 2: 1.
64. Launay-Vacher V, Chatelut E, Lichtman S, et al. Renal insufficiency in elderly cancer patients: International Society of Geriatric Oncology clinical practice recommendations. Ann Oncol 2007; 18: 1314–1321.
65. Owonikoko TK, Ragin CC, Belani CP, et al. Lung cancer in elderly patients: an analysis of the surveillance, epidemiology, and end results database. J Clin Oncol 2007; 25: 5570–5577.
66. Islam KMM, Jiang X, Anggondowati T, et al. Comorbidity and survival in lung cancer patients. Cancer Epidemiol Biomarkers Prev 2015; 24: 1079–1085.
67. Wild S, Roglic G, Green A, et al. Global prevalence of diabetes: estimates for the year 2000 and projections for 2030. Diabetes Care 2004; 27: 1047–1053.
68. Sciacca L, Vigneri R, Tumminia A, et al. Clinical and molecular mechanisms favoring cancer initiation and progression in diabetic patients. Nutr Metab Cardiovasc Dis 2013; 23: 808–815.
69. Arcidiacono B, Iiritano S, Nocera A, et al. Insulin resistance and cancer risk: an overview of the pathogenetic mechanisms. Exp Diabetes Res 2012; 2012: 789174.
70. Noto H, Tsujimoto T, Sasazuki T, et al. Significantly increased risk of cancer in patients with diabetes mellitus: a systematic review and meta-analysis. Endocr Pract 2011; 17: 616–628.
71. Zeng G, Rui W, Grouse L. Diabetes mellitus increases postoperative mortality in non-small cell lung cancer. Thorac Cancer 2014; 5: 111.
72. Tseng C-H. Higher risk of mortality from lung cancer in Taiwanese people with diabetes. Diabetes Res Clin Pract 2013; 102: 193–201.
73. Falcoz PE, Conti M, Brouchet L, et al. The Thoracic Surgery Scoring System (Thoracoscore): risk model for in-hospital death in 15,183 patients requiring thoracic surgery. J Thorac Cardiovasc Surg 2007; 133: 325–332.
74. Powell HA, Tata LJ, Baldwin DR, et al. Early mortality after surgical resection for lung cancer: an analysis of the English National Lung cancer audit. Thorax 2013; 68: 826–834.
75. Kaw R, Chung F, Pasupuleti V, et al. Meta-analysis of the association between obstructive sleep apnoea and postoperative outcome. Br J Anaesth 2012; 109: 897–906.
76. Benzo R, Wigle D, Novotny P, et al. Preoperative pulmonary rehabilitation before lung cancer resection: results from two randomized studies. Lung Cancer 2011; 74: 441–445.
77. Lorut C, Lefebvre A, Planquette B, et al. Early postoperative prophylactic noninvasive ventilation after major lung resection in COPD patients: a randomized controlled trial. Intensive Care Med 2014; 40: 220–227.
78. Thomas PA, Berbis J, Falcoz PE, et al. National perioperative outcomes of pulmonary lobectomy for cancer: the influence of nutritional status. Eur J Cardiothorac Surg 2014; 45: 652–659; discussion 659.
79. Mashour GA, Shanks AM, Kheterpal S. Perioperative stroke and associated mortality after noncardiac, nonneurologic surgery. Anesthesiology 2011; 114: 1289–1296.
80. European Stroke O,Tendera M, Aboyans V, et al. ESC Guidelines on the diagnosis and treatment of peripheral artery diseases: Document covering atherosclerotic disease of extracranial carotid and vertebral, mesenteric, renal, upper and lower extremity arteries: the Task Force on the Diagnosis and Treatment of Peripheral Artery Diseases of the European Society of Cardiology (ESC). Eur Heart J 2011; 32: 2851–2906.
81. Lim E, Baldwin D, Beckles M, et al. Guidelines on the radical management of patients with lung cancer. Thorax 2010; 65: Suppl. 3, iii1–ii27.
82. Brunelli A, Charloux A, Bolliger CT, et al. ERS-ESTS clinical guidelines on fitness for radical therapy in lung cancer patients (surgery and radiochemotherapy). Eur Respir J 2009; 34: 17–41.
83. Brunelli A, Kim AW, Berger KI, et al. Physiologic evaluation of the patient with lung cancer being considered for resectional surgery: diagnosis and management of lung cancer, 3rd ed: American College of Chest Physicians evidence-based clinical practice guidelines. Chest 2013; 143: e166S–e190S.
84. Hammill BG, Curtis LH, Bennett-Guerrero E, et al. Impact of heart failure on patients undergoing major noncardiac surgery. Anesthesiology 2008; 108: 559–567.
85. Kazmers A, Cerqueira MD, Zierler RE. Perioperative and late outcome in patients with left ventricular ejection fraction of 35% or less who require major vascular surgery. J Vasc Surg 1988; 8: 307–315.
86. Healy KO, Waksmonski CA, Altman RK, et al. Perioperative outcome and long-term mortality for heart failure patients undergoing intermediate- and high-risk noncardiac surgery: impact of left ventricular ejection fraction. Congest Heart Fail 2010; 16: 45–49.
87. Kristensen SD, Knuuti J, Saraste A, et al. 2014 ESC/ESA Guidelines on non-cardiac surgery: cardiovascular assessment and management: The Joint Task Force on non-cardiac surgery: cardiovascular assessment and management of the European Society of Cardiology (ESC) and the European Society of Anaesthesiology (ESA). Eur Heart J 2014; 35: 2383–2431.
88. Seppenwoolde Y, Lebesque JV. Partial irradiation of the lung. Semin Radiat Oncol 2001; 11: 247–258.
89. Rodrigues G, Lock M, D’Souza D, et al. Prediction of radiation pneumonitis by dose–volume histogram parameters in lung cancer - a systematic review. Radiother Oncol 2004; 71: 127–138.
90. Seppenwoolde Y, Lebesque JV, de Jaeger K, et al. Comparing different NTCP models that predict the incidence of radiation pneumonitis. Normal tissue complication probability. Int J Radiat Oncol Biol Phys 2003; 55: 724–735.
91. Brooks BJ Jr, Seifter EJ, Walsh TE, et al. Pulmonary toxicity with combined modality therapy for limited stage small-cell lung cancer. J Clin Oncol 1986; 4: 200–209.
92. Yamada M, Kudoh S, Hirata K, et al. Risk factors of pneumonitis following chemoradiotherapy for lung cancer. Eur J Cancer 1998; 34: 71–75.
93. Lee JS, Scott C, Komaki R Jr, et al. Concurrent chemoradiation therapy with oral etoposide and cisplatin for locally advanced inoperable non-small-cell lung cancer: radiation therapy oncology group protocol 91-06. J Clin Oncol 1996; 14: 1055–1064.
94. Byhardt RW, Scott C, Sause WT, et al. Response, toxicity, failure patterns, and survival in five Radiation Therapy Oncology Group (RTOG) trials of sequential and/or concurrent chemotherapy and radiotherapy for locally advanced non-small-cell carcinoma of the lung. Int J Radiat Oncol Biol Phys 1998; 42: 469–478.
95. Robert F, Childs HA, Spencer SA, et al. Phase I/IIa study of concurrent paclitaxel and cisplatin with radiation therapy in locally advanced non-small cell lung cancer: analysis of early and late pulmonary morbidity. Semin Radiat Oncol 1999; 9: 136–147.
96. Monson JM, Stark P, Reilly JJ, et al. Clinical radiation pneumonitis and radiographic changes after thoracic radiation therapy for lung carcinoma. Cancer 1998; 82: 842–850.
97. Robnett TJ, Machtay M, Vines EF, et al. Factors predicting severe radiation pneumonitis in patients receiving definitive chemoradiation for lung cancer. Int J Radiat Oncol Biol Phys 2000; 48: 89–94.
98. Rancati T, Ceresoli GL, Gagliardi G, et al. Factors predicting radiation pneumonitis in lung cancer patients: a retrospective study. Radiother Oncol 2003; 67: 275–283.
99. Claude L, Perol D, Ginestet C, et al. A prospective study on radiation pneumonitis following conformal radiation therapy in non-small-cell lung cancer: clinical and dosimetric factors analysis. Radiother Oncol 2004; 71: 175–181.
100. Jeremic B, Shibamoto Y, Acimovic L, et al. Hyperfractionated radiation therapy with or without concurrent low-dose daily carboplatin/etoposide for stage III non-small-cell lung cancer: a randomized study. J Clin Oncol 1996; 14: 1065–1070.
101. Quon H, Shepherd FA, Payne DG, et al. The influence of age on the delivery, tolerance, and efficacy of thoracic irradiation in the combined modality treatment of limited stage small cell lung cancer. Int J Radiat Oncol Biol Phys 1999; 43: 39–45.
102. Hernando ML, Marks LB, Bentel GC, et al. Radiation-induced pulmonary toxicity: a dose-volume histogram analysis in 201 patients with lung cancer. Int J Radiat Oncol Biol Phys 2001; 51: 650–659.
103. Yamaguchi S, Ohguri T, Matsuki Y, et al. Radiotherapy for thoracic tumors: association between subclinical interstitial lung disease and fatal radiation pneumonitis. Int J Clin Oncol 2015; 20: 45–52.
104. Schaake-Koning C, van den Bogaert W, Dalesio O, et al. Effects of concomitant cisplatin and radiotherapy on inoperable non-small-cell lung cancer. N Engl J Med 1992; 326: 524–530.
105. Sculier JP, Botta I, Bucalau AM, et al. Medical anticancer treatment of lung cancer associated with comorbidities: a review. Lung Cancer 2015; 87: 241–248.
106. Pai VB, Nahata MC. Cardiotoxicity of chemotherapeutic agents: incidence, treatment and prevention. Drug Saf 2000; 22: 263–302.
107. Lichtman SM, Wildiers H, Launay-Vacher V, et al. International Society of Geriatric Oncology (SIOG) recommendations for the adjustment of dosing in elderly cancer patients with renal insufficiency. Eur J Cancer 2007; 43: 14–34.
108. Kuo JC, Craft PS. Administration of chemotherapy in patients on dialysis. Anticancer Drugs 2015; 26: 779–784.
109. Isobe K, Hata Y, Sakamoto S, et al. Clinical characteristics of acute respiratory deterioration in pulmonary fibrosis associated with lung cancer following anti-cancer therapy. Respirology 2010; 15: 88–92.
110. Minegishi Y, Takenaka K, Mizutani H, et al. Exacerbation of idiopathic interstitial pneumonias associated with lung cancer therapy. Intern Med Tokyo Jpn 2009; 48: 665–672.
111. Pavlakis N, Bell DR, Millward MJ, et al. Fatal pulmonary toxicity resulting from treatment with gemcitabine. Cancer 1997; 80: 286–291.
112. Read WL, Mortimer JE, Picus J. Severe interstitial pneumonitis associated with docetaxel administration. Cancer 2002; 94: 847–853.
113. Okuda K, Hirose T, Oki Y, et al. Evaluation of the safety and efficacy of combination chemotherapy with vinorelbine and platinum agents for patients with non-small cell lung cancer with interstitial lung disease. Anticancer Res 2012; 32: 5475–5480.
114. Créquit P, Wislez M, Fleury Feith J, et al. Crizotinib associated with ground-glass opacity predominant pattern interstitial lung disease: a retrospective observational cohort study with a systematic literature review. J Thorac Oncol 2015; 10: 1148–1155.
115. Naito Y, Tsuchiya S, Ishihara S, et al. Impact of preexisting pulmonary fibrosis detected on chest radiograph and CT on the development of gefitinib-related interstitial lung disease. Am J Clin Oncol 2008; 31: 340–344.
116. Rossi A, Maione P, Gaizo FD, et al. Safety profile of gefitinib in advanced non-small cell lung cancer elderly patients with chronic renal failure: two clinical cases. Lung Cancer 2005; 47: 421–423.
117. Togashi Y, Masago K, Fukudo M, et al. Pharmacokinetics of erlotinib and its active metabolite OSI-420 in patients with non-small cell lung cancer and chronic renal failure who are undergoing hemodialysis. J Thorac Oncol 2010; 5: 601–605.
118. Brahmer J, Reckamp KL, Baas P, et al. Nivolumab versus docetaxel in advanced squamous-cell non-small-cell lung cancer. N Engl J Med 2015; 373: 123–135.
119. Borghaei H, Paz-Ares L, Horn L, et al. Nivolumab versus docetaxel in advanced nonsquamous non-small-cell lung cancer. N Engl J Med 2015; 373: 1627–1639.
120. Herbst RS, Baas P, Kim D-W, et al. Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trial. Lancet 2016; 387: 1540–1550.
121. Reck M, Rodríguez-Abreu D, Robinson AG, et al. Pembrolizumab versus chemotherapy for PD-L1-positive non-small-cell lung cancer. N Engl J Med 2016; 375: 1823–1833.
122. Howell M, Lee R, Bowyer S, et al. Optimal management of immune-related toxicities associated with checkpoint inhibitors in lung cancer. Lung Cancer Amst Neth 2015; 88: 117–123.
123. Quoix E, Zalcman G, Oster J-P, et al. Carboplatin and weekly paclitaxel doublet chemotherapy compared with monotherapy in elderly patients with advanced non-small-cell lung cancer: IFCT-0501 randomised, phase 3 trial. Lancet 2011; 378: 1079–1088.
124. Lavolé A, Tomasini P, Monnet I, et al. IFCT-1001 CHIVA trial: a phase II study of carboplatin (Ca) plus pemetrexed (P) followed by P maintenance, as first-line therapy for human immunodeficiency virus (HIV)–associated advanced non-squamous non-small cell lung cancer (NS-NSCLC). J Clin Oncol 2016; 34: Suppl., 9076.
125. Nilssen Y, Strand TE, Fjellbirkeland L, et al. Lung cancer treatment is influenced by income, education, age and place of residence in a country with universal health coverage. Int J Cancer 2016; 138: 1350–1360.
126. Ju H, Kim S, Read P, et al. Development of a novel remote-controlled and self-contained audiovisual-aided interactive system for immobilizing claustrophobic patients. J Appl Clin Med Phys 2015; 16: 5359.
127. Li G, Lovelock DM, Mechalakos J, et al. Migration from full-head mask to “open-face” mask for immobilization of patients with head and neck cancer. J Appl Clin Med Phys 2013; 14: 243–254.
128. Néron S, Stephenson R. Effectiveness of hypnotherapy with cancer patients’ trajectory: emesis, acute pain, and analgesia and anxiolysis in procedures. Int J Clin Exp Hypn 2007; 55: 336–354.
129. Wheeler SB, Kuo T-M, Durham D, et al. Effects of distance to care and rural or urban residence on receipt of radiation therapy among North Carolina Medicare enrollees with breast cancer. N C Med J 2014; 75: 239–246.
130. Davidoff AJ, Tang M, Seal B, et al. Chemotherapy and survival benefit in elderly patients with advanced non-small-cell lung cancer. J Clin Oncol 2010; 28: 2191–2197.
131. Quoix E, Monnet I, Scheid P, et al. [Management and outcome of French elderly patients with lung cancer: an IFCT survey]. Rev Mal Respir 2010; 27: 421–430.